Marinomed Biotech Ag · VIE:MARI
Marinomed Biotech — FY2019 Earnings Presentation
18 slides from Marinomed Biotech's earnings presentation, Apr 16, 2020
Slide 1: Creating innovative therapies for respiratory, allergy and eye diseases
Creating innovative therapies for respiratory, allergy and eye diseases Results for 2019 – COVID-19 - 2020 Investor Presentation Vienna, 16th April 2020
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Record year 2019 and positive outlook 2020
Record year 2019 and positive outlook 2020 Important milestones provide basis for accelerated development going forward €37.4m Phase III COVID-19 Budesolv with strong Increases demand for Financing through IPO results – technology virus blockers and EIB platform validated +31% Free Float 58% Revenue
Slide 4: Agenda
Agenda Marinomed – the future with COVID-19 Sars-CoV-2 and the danger of respiratory viruses Growth prospects for Carragelose® Marinosolv®: innovation and better products drive the market The year 2019 in numbers Strong Outlook 2020 4
Slide 5: Sars-CoV-2 is a respiratory virus
Sars-CoV-2 is a respiratory virus Infections with respiratory viruses regularly lead to hospitalisation Hospitalised Kids with pneumonia 2010-2012, USA Respiratory Viruses are by far the major cause of pneumonia in kids Coronaviruses have been around for quite some time Source: Jain et al., NEJM 372
Slide 6: Pre-existing illnesses worsen symptoms
Pre-existing illnesses worsen symptoms Symptoms are dramatically higher and last longer Rhinoviruses cause worsening of symptoms Rhinoviruses cause virus titers to peak a day in >95% of COPD* patients1 earlier and are 10x higher in Asthma patients2 COPD and Asthma patients are a high risk population
Slide 7: Typical proliferation of respiratory viruses
Typical proliferation of respiratory viruses Finally, a virus will spread to every person in a system Within one month, the rhinovirus infected every person (incl. staff) in a retirement home 56 residents 87,6y mean age pathogen HRV-82 Respiratory pathogens, such as rhinovirus, causing only mild sym
Slide 8: Marinomed has relevant experience
Marinomed has relevant experience Carragelose ® is successfully treating virus related symptoms since 2008 Carragelose ® binds Corona viruses (no data for Sars-CoV-2) Post hoc clinical data from 2 double blind placebo controlled trials Group Rhino Corona1 Influenza A 8.8 ± 0.6 9.0 ± 0.7 8.7 ± 1.0 Pl
Slide 9: Positive impact on product sales
: Positive impact on product sales Current pandemic results in improved perspective for Carragelose ® segment COVID-19 increases the demand for virus blocking products Demand for Carragelose® products results in prolonged high season Data from Austria suggest that once the product is understoo
Slide 10: with advanced pipeline
with advanced pipeline Advanced pipeline of Marinosolv® enabled compounds 1 Nose 3 Ophthalmology Budesolv in allergic rhinitis Tacrosolv in allergic conjunctivitis phase III completed, in registration phase II in 2020* Flutisolv Tacrosolv in dry eyes disease phase III ready phase III in 2021/22* Oth
Slide 11: Carragelose segment with solid growth
Carragelose® segment with solid growth Growth path of Carragelose ® maintained throughout the year 2019 and beyond Revenue by Year (in m€) Comments 8.0 Double digit growth in revenue from the sale of 6.1 products in the Carragelose ® segment achieved 6.0 4.8 4.7 Return of certain regions results
Slide 12: Statement of profit or loss (IFRS)
Statement of profit or loss (IFRS) €m 2019 2018 1 Revenue €m 2019 2018 Revenues 1 6.1 4.7 Sale of goods 4.9 4.4 License revenues 1.0 0.1 Other income 0.7 0.7 Other revenues 0.3 0.1 Other net gains/losses 0.0 0.0 Total revenue 6.1 4.7 Materials expenses 2 (3.6) (3.3) Services expenses 2 (3.1) (1.5) R
Slide 13: Statement of financial position (IFRS)
Statement of financial position (IFRS) Assets €m 2019 2018 1 Acquisition of property in Korneuburg (€0.4m) as well as assets under construction (€1.8m) Assets Intangible assets 1.6 1.3 2 Therein Austrian Research Promotion in the amount of €0.9m (2018: €0.5m) Property, plant and equipment 1 2.5 0.2
Slide 14: Statement of financial position (IFRS)
Statement of financial position (IFRS) Equity and liabilities €m 2019 2018 1 Therein IPO related paid-in capital of €20.3m (net of transaction costs) and conversion of the Equity and liabilities convertible bond in the amount of €13.1m Share capital 1.5 1.0 Capital reserves 2 Primarily related to fi
Slide 15: Statement of cash flows (IFRS)
Statement of cash flows (IFRS) Net Cash at Net change in Net D&A Cash at beginning Loss for financial working interest and Investing Financing end of of period the period result capital paid other cash flow cash flow period 15
Slide 16: Short-term COVID-19 impact on Marinomed
Short-term COVID-19 impact on Marinomed Increased demand for Carragelose ® products and some short term delays in trails High demand for Carragelose ® products Close contact with partner producers to increase production Supply chain management is the main challenge in 2020 Pandemic-related, shor
Slide 17: Positive Outlook 2020
Positive Outlook 2020 Investments in Marinosolv® and commercialisation of Carragelose® COVID-19 boosts demand for virus blocking products Marinomed’s technology platforms are broadly and excellent positioned Marinomed is involved in extensive national and international research activities Strong
Slide 18: www.marinomed.com
: ( marino www.marinomed.com : oe